TGF‐β1 has been identified as a key profibrotic factor in airway fibrosis, and its inhibition has been explored as a therapeutic approach for various fibrotic diseases, including idiopathic pulmonary fibrosis and renal fibrosis [23, 24]. Here, TGFB1 is linked to pulmonary fibrosis.